Satellite Banner
Molecular & Clinical Diagnostics
Scientific Community
 
Become a Member | Sign in
Home>Products>This Product
  Products


LeadCare® II

Product Image
Product Description

LeadCare® II is the only CLIA-waived, point-of-care lead testing system that makes it possible to test, educate and intervene on-the-spot, in one visit. No need to send patients to an outside lab. No need to re-test due to sample problems at the lab. No risk of losing track of a child who needs treatment.

Who should be tested?

Federal law requires that all Medicaid eligible children be tested at 12 and 24 months and ages 36 to 72 months if they have not previously been tested.

Each state has guidelines for blood lead testing.  The American  Academy of Pediatrics (AAP) recommends that “children should be tested at least once when they are 2 years of age or, ideally, twice, at 1 and 2 years of age, unless lead exposure can be confidently excluded.”4

Contact us for information to help you determine your state’s specific testing requirements.

Who is at risk for lead exposure? Children are considered at risk if any of the following are true4:
•    Child lives in or frequently visits a home built before 1950, or a recently renovated home built before 1978
•    Child has a sibling or frequent playmate with elevated blood lead levels
•    Child's parent or primary caregiver works with lead. Examples include: battery recycling or manufacture, lead smelting, lead mining, auto repair, shipbuilding, construction, plumbing, and glass manufacture5
•    Child is a recent immigrant, refugee, or foreign adoptee.
•    Child has a household member who uses traditional, folk, or ethnic remedies or cosmetics or who routinely eats food imported informally (e.g., by a family member)

No safe levels. Evidence continues to grow that blood lead levels as low as 5 ug/dL may impair cognition3, with no minimum threshold yet identified.

Lifelong consequences of lead exposure include:
•    Six times higher likelihood of having a reading disability6
•    Being seven times more likely to drop out of high school6
•    Lower scores on neurobehavioral development7
•    Lower scores on tests for math, reading, nonverbal reasoning and short term memory7
•    Hypertension that contributes to adult cardiovascular disease8
•    Decline in IQ with every 1.0 μg/dL increase in blood lead9

Early diagnosis helps to quickly address the effects of lead exposure and provides impetus for lead abatement in homes.

LeadCare II is the only CLIA-waived point-of-care blood lead testing system. Employees of an office or lab operating under a CLIA Certificate of Waiver can administer the test.

Product LeadCare® II
Company Magellan Diagnostics
Price Request a quote
More Information View company product page
Catalog Number Unspecified
Quantity Unspecified
Company Logo

Magellan Diagnostics
101 Billerica Ave, Building 4 North Billerica, MA 01862 USA

Tel: +1 800-959-5095
Fax: +1 800-755-5095
Email: orders@magellanbio.com



Scientific News
Accelerating the Detection of Foodborne Bacterial Outbreaks
The speed of diagnosis of foodborne bacterial outbreaks could be improved by a new technique developed by researchers at the Georgia Institute of Technology.
Cancer Gene Predicts Treatment Response in Leukaemia
Study indicates the patients suffering from a lethal for of acute myeloid leukemia may live longer when receiving milder chemotherapy drugs.
New Diagnostic Tool for Familial Mediterranean Fever
A new tool developed by researchers at VIB and Ghent University could improve the process of diagnosing Familial Mediterranean Fever.
'Lab on the Skin' for Sweat Analysis
Northwestern University researchers develop a low-cost wearable electronic device that collects and analyzes sweat for health monitoring.
Molecular Signature for Aggressive Brain Tumor Uncovered
Researchers have identified genetic mutations in a highly agressive brain cancer that distinguishes the agressive, from the benign forms of the cancer.
Malaria Parasite Evades Rapid Test Detection in Children
A study at the University of North Carolina found that gene deletion poses a threat to Malaria eradication efforts.
Novel Urine Test to Predict High-Risk Cervical Cancer
Preliminary studies affirm accuracy and potential cost savings to screen for virus-caused malignancy.
GFC Diagnostics Wins Longitude Prize Discovery Award
The global award was won for the development of a cheap, quick and simple MRSA Test.
Understanding Circulating Tumour Cells
Research team develops new tool to track traveling cancer cells in the bloodstream.
Blood Glucose Monitoring Device for Diabetes
Novel breathalyzer offers alternative to finger stick testing for people with type 1 and 2 diabetes.

Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
4,000+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,300+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!